Novel therapeutic agents, like biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs), have transformed the prognostic landscape for people living with rheumatoid arthritis (RA) in recent years. However, the future looks potentially a great deal less promising. Year after year, one randomized, double-blind, placebo-controlled trial after another, placebo response rates have escalated, now accounting for 40% to more than 60% of the observed benefit, severely narrowing the detectable therapeutic margin.1,4,10
What this means for RA therapeutic agents still in clinical development is dire. Regulatory authorization of efficacious molecules could be at risk. Sponsors need strategies to mitigate placebo response in RA clinical trials, and they need them now.
In this first article in a three-part series, we will explore the underlying causes of placebo response in RA trials. A better understanding of these drivers helps in the development of operational strategies to mitigate the distortion of signal through placebo noise. The inflated placebo response rate in RA trials is as complex as the disease itself. The placebo response rate is the synergistic outcome of socioeconomics, pharmacological and psycho-neurobiological factors, as well as methodological artifacts inherent to the rigorous monitoring environments of clinical trials.
Socioeconomic Recruitment Patterns Globally
The globalization of clinical trials has increasingly shifted patient recruitment toward low- and middle-income countries, a transition that has profoundly affected baseline placebo response rates. Recent meta-regression analyses encompassing hundreds of trials and thousands of RA patients have demonstrated a profound negative association between the gross national income (GNI) of the recruiting region and the magnitude of the placebo response.2
For every decrease of $10,000 international dollars in per-capita GNI, the placebo American College of Rheumatology 20% (ACR20) response increases by nearly 4%.2 This finding remains statistically robust even after controlling for potential confounders such as baseline disease duration and severity.
This phenomenon in global recruitment is primarily driven by systemic healthcare disparities. In less affluent regions where access to advanced, high-cost biological therapies or targeted synthetic agents is limited, clinical trial participation is a highly valuable avenue to receive state-of-the-art medical care. This socioeconomic dynamic dramatically amplifies expectation bias, as patients harbor intense psychological anticipation of therapeutic benefit.
Furthermore, regional analyses reveal distinct disparities in adverse event (AE) reporting, with certain regions (notably Russia and Eastern Europe) demonstrating significantly lower AE reporting rates in placebo arms (22% vs. 51â53% in Asia, Latin America and the USA5), suggesting a cultural or access-driven reluctance to report issues that might jeopardize trial continuation5. Consequently, patients in lower GNI regions show significantly higher placebo responses, while active treatment responses remain relatively stable across geographies, effectively diluting the overall measurable treatment effect on a global scale.2
Enhanced Adherence to Background Therapy
To satisfy ethical standards of care, the majority of contemporary Phase 2 and 3 RA clinical trials require participants to maintain a stable background dose of conventional synthetic DMARDs (csDMARDs), predominantly methotrexate (MTX). However, retrospective analyses of pivotal RA trials, including the GO-AFTER and SIRROUND-T cohorts, have identified a critical methodological artifact: clinical response rates in placebo cohorts are significantly inflated among patients continuing background MTX compared to those receiving placebo as monotherapy.
Specifically, patients continuing MTX demonstrated more than double the ACR20 response rate (25.3% vs. 12.4%, p = 0.005) and a nearly tenfold increase in ACR50 responses (8.4% vs. 0.9%, p = 0.003), as well as significantly higher rates of Clinical Disease Activity Index (CDAI) low disease activity (8.8% vs. 1.8%, p = 0.013)3. This statistical disparity is driven by the inadvertent “consequent intake” phenomenon. Prior to trial enrollment, patients classified as MTX-inadequate responders (MTX-IR) often show substantial non-compliance with their baseline regimen, frequently due to gastrointestinal intolerance, fatigue, or a general lack of perceived efficacy.
However, upon entering the highly monitored environment of a Phase 2 or 3 clinical trial, which mandates regular pill counts, rigorous clinical follow-ups, and intense medical scrutiny, patient adherence to their previously “inadequate” background therapy improves dramatically. The subsequent improvement in disease activity is captured algorithmically as a placebo response when, in reality, it reflects the delayed pharmacological efficacy of newly optimized background MTX adherence.3
Natural Disease Fluctuation & Regression to the Mean
RA is characterized inherently by a relapsing-remitting course with symptoms oscillating over time. Clinical trial inclusion criteria typically mandate a stringent threshold of high disease activity, such as a minimum of six swollen and six tender joints alongside elevated acute-phase reactants, at the exact time of screening and baseline evaluation. Selecting patients precisely at the peak of a disease flare mathematically guarantees a subsequent downward trajectory in disease activity metrics upon follow-up, a statistical artifact universally known as regression to the mean (RTM).4,7,8 Indeed, in routine RA practice, as much as one-third of the apparent DAS improvement on TNF-α inhibitors (0.6 of 1.8 points) has been attributed to RTM alone.7
While it is widely accepted that subjective outcomes10, such as patient-reported pain in rheumatic diseases and global assessments, are highly susceptible to RTM, empirical evidence demonstrates that objective biomarkers are equally impacted. Comprehensive cross-sectional studies of placebo arms in double-blind RA trials have shown statistically significant decreases in objective inflammatory markers, specifically C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), alongside reductions in subjective pain intensity.4
This indicates that the improvements observed in placebo cohorts are not solely psychogenic or subjective illusions; they represent genuine physiological regression from an extreme state of baseline inflammation, confounding the ability to detect true drug-induced modifications.8
(Negative) Hawthorne Effect & Expectation Bias
The Hawthorne effect traditionally describes altered patient behavior resulting from the awareness of being observed, typically leading to improved outcomes. However, in the context of pain and chronic inflammatory diseases, trialists must account for the “negative Hawthorne effect” or symptom overexpression during the screening phase.6 Patients who are eager to access novel therapeutics may consciously or subconsciously overexpress their pain and functional limitations to ensure they meet the stringent severity criteria required for trial inclusion. Once randomized and secure in the trial, this overexpression subsides, resulting in a dramatic, artificial drop in pain scores that is misclassified as a therapeutic placebo response.6
Compounding this is standard expectation bias1. Placebo analgesia is a genuine neurobiological phenomenon mediated by the activation of endogenous opioid and dopaminergic pathways in the central nervous system, triggered by the expectation of relief and the therapeutic ritual of receiving an injection or infusion.9,10 Because primary composite endpoints in RA, such as the ACR20/50/70 and the Disease Activity Score (DAS28), heavily incorporate subjective patient-reported outcomes, a strong neurologically mediated analgesic placebo effect can push a patient over the responder threshold despite a complete lack of objective reduction in peripheral synovial inflammation.
To combat the persistent escalation of placebo response rates in RA clinical trials, a sponsor needs strategies to overcome this formidable, multifaceted barrier to the successful development and regulatory approval of novel therapeutics. Clinical development teams must implement rigorous, multi-layered operational control measures that span from the very inception of the protocol to the final submission of the Clinical Study Report.
The next article in this three-part series will look at comprehensive operational strategies to mitigate placebo response in RA clinical trials, specifically from protocol to site-level execution.
About the author
Dr. Juan Ovalles, MD, PhD, Senior Medical Director of Rheumatology at Indero, providing medical leadership and strategic guidance in rheumatology research. He collaborates with business development, supports operational and regulatory teams, and builds relationships with key stakeholders. With more than 14 years of clinical development experience, Dr. Ovalles began his career as an investigator in 2012 and transitioned to the CRO industry in 2021. A board-certified rheumatologist with a PhD in biomedical sciences, he specializes in innovative therapies for immune-mediated, inflammatory diseases.
References & Recommended Reading
- Bechman K, Yates M, Norton S, Cope AP, Galloway JB. Placebo Response in Rheumatoid Arthritis Clinical Trials. J Rheumatol. 2020 Jan;47(1):28-34. doi: 10.3899/jrheum.190008. Epub 2019 May 1. PMID: 31043548; PMCID: PMC6941937.
- Kerschbaumer A, Steiner M, Pruckner P, Wildner B, Maad M, Smolen JS, Aletaha D. Global recruitment patterns and placebo responses in clinical trials of rheumatoid arthritis. Ann Rheum Dis. 2025 Oct;84(10):1632-1640. doi: 10.1016/j.ard.2025.07.010. Epub 2025 Aug 5. PMID: 40752975.
- Kerschbaumer A, Rivai ZI, Smolen JS, Aletaha D. Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis. Ann Rheum Dis. 2022 Oct;81(10):1374-1378. doi: 10.1136/annrheumdis-2021-221807. Epub 2022 Jun 20. PMID: 35725294.
- Vollert J, Cook NR, Kaptchuk TJ, Sehra ST, Tobias DK, Hall KT. Assessment of Placebo Response in Objective and Subjective Outcome Measures in Rheumatoid Arthritis Clinical Trials. JAMA Netw Open. 2020 Sep 1;3(9):e2013196. doi: 10.1001/jamanetworkopen.2020.13196. PMID: 32936297; PMCID: PMC7495232.
- Keebler D, Teng E, Chia J, Galanter J, Peake J, Tuckwell K. Regional variations in adverse event reporting rates and ACR responses in placebo/standard-of-care arms of rheumatoid arthritis trials. Rheumatology (Oxford). 2020 Oct 1;59(10):3023-3031. doi: 10.1093/rheumatology/keaa043. PMID: 32182362; PMCID: PMC7516100.
- Berthelot JM, Nizard J, Maugars Y. The negative Hawthorne effect: Explaining pain overexpression. Joint Bone Spine. 2019 Jul;86(4):445-449. doi: 10.1016/j.jbspin.2018.10.003. Epub 2018 Oct 11. PMID: 30316973.
- Greenwood MC, Rathi J, Hakim AJ, Scott DL, Doyle DV. Regression to the mean using the disease activity score in eligibility and response criteria for prescribing TNF-alpha inhibitors in adults with rheumatoid arthritis. Rheumatology (Oxford). 2007 Jul;46(7):1165-7. doi: 10.1093/rheumatology/kem109. Epub 2007 May 7. PMID: 17488751.
- Chen YT, Zhu G, Hassett AL, Clauw D, Murphy SL. Considerations for Issues of Regression to the Mean and Contextual Effects in Clinical Trials for Pain in Rheumatic Diseases. Arthritis Care Res (Hoboken). 2026 Jan;78(1):31-37. doi: 10.1002/acr.25636. Epub 2025 Sep 25. PMID: 40827008; PMCID: PMC12826090.
- Zubieta JK, Stohler CS. Neurobiological mechanisms of placebo responses. Ann N Y Acad Sci. 2009 Mar;1156:198-210. doi: 10.1111/j.1749-6632.2009.04424.x. PMID: 19338509; PMCID: PMC3073412.
- Abhishek A, Doherty M. Understanding placebo effects in rheumatology. Joint Bone Spine. 2015 Jul;82(4):222-4. doi: 10.1016/j.jbspin.2015.01.013. Epub 2015 Mar 13. PMID: 25776451.
- Abdullah N. Placebo effect in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials [abstract THU0189]. Ann Rheum Dis. 2015;74(Suppl 2):263. doi:10.1136/annrheumdis-2015-eular.4519.
